AU-101 / Aurora Biopharma, Baylor College of Medicine - LARVOL DELTA

iCAR: T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors (clinicaltrials.gov) - P1 | N=10 | Active, not recruiting | Sponsor: Baylor College of Medicine | Recruiting ➔ Active, not recruiting | N=28 ➔ 10 | Trial completion date: Jan 2036 ➔ Apr 2037

Enrollment change • Enrollment closed • Trial completion date • Brain Cancer • Breast Cancer • CNS Tumor • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2

'Puppy Dog Eyes' Are Associated With Eye Movements, Not Communication. (PubMed, Front Psychol) - "We further demonstrate that the inner brow raiser is strongly associated with eye movements and occurs independently in only 6% of cases. This result challenges the hypothesis that the inner brow raiser has a communicative function in dog-human interactions and suggests a lower-level explanation for its production, namely an association with eye movements."

Journal

INDUS-2: A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis (clinicaltrials.gov) - P2; N=90; Active, not recruiting; Sponsor: Aurigene Discovery Technologies Limited; Recruiting ➔ Active, not recruiting; Trial primary completion date: Nov 2020 ➔ Mar 2021

Clinical • Enrollment closed • Trial primary completion date • Dermatology • Immunology • Psoriasis

Equine Facial Action Coding System for determination of pain-related facial responses in videos of horses. (PubMed, PLoS One) - "The inner brow raiser (AU101) and eye white increase (AD1) had less consistent results across experimental and clinical data...In particular, chewing (AD81) was found to be indicative of pain. Lastly, we identified increased frequency of half blink (AU47) as a new indicator of pain in the horses of this study."

Journal • Pain

Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents. (PubMed, Vaccine) - "The likelihood of this program being cost-effective under a willingness to pay threshold AU$50,000 per QALY gained is 35%."

HEOR • Journal • CNS Disorders • Infectious Disease

INDUS-2: A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis (clinicaltrials.gov) - P2; N=90; Recruiting; Sponsor: Aurigene Discovery Technologies Limited; Not yet recruiting ➔ Recruiting

Enrollment open

INDUS-2: A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis (clinicaltrials.gov) - P2; N=90; Not yet recruiting; Sponsor: Aurigene Discovery Technologies Limited

Clinical • New P2 trial